Previous 10 | Next 10 |
INVO Bioscience Advances Commercialization into the European Fertility Market with Initial Orders of INVOcell (IVC) in Spain - Spain marks INVO's initial entry into the European market - Europe represents approximately 30% of the multi-billion dollar global fertility marketp...
INVO Bioscience (INVO) enters an exclusive distribution agreement with Galaxy Pharma to distribute the INVOcell system within Pakistan.Galaxy Pharma is a leader in providing products and services to the country's current full-service In Vitro Fertilization or IVF faci...
INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd. - Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan - Seeks to expand access to infertil...
INVO Bioscience Management Letter to Shareholders Key Developments and Future Initiatives Position INVOcell® Within the Severely Underserved Fertility Market PR Newswire SARASOTA, Fla. , Jan. 7, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INV...
INVO Bioscience and idsMED Group Enter Distribution Agreement for Malaysia - Malaysia represents a significant addressable market opportunity with approximately 10% of the population suffering from infertility. - idsMED is one of the largest and most well-respected medical s...
INVO Bioscience, Inc. (INVO) Q3 2020 Results Conference Call November 19, 2020 04:30 PM ET Company Participants Robert Blum - Lytham Partners Steven Shum - CEO Michael Campbell - COO and Head of Business Development Conference Call Participants Presentation Operator Good afternoon and welcome...
INVO Bioscience Forms Scientific Advisory Board with Leaders from Fertility Industry PR Newswire SARASOTA, Fla., Nov. 18, 2020 SARASOTA, Fla. , Nov. 18, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) developers of INVOcell®, the world's on...
INVO BioScience (INVO): Q3 GAAP EPS of -$0.36.Revenue of $0.34M (+13.3% Y/Y)Press Release For further details see: INVO BioScience reports Q3 results
INVO Bioscience Reports Third Quarter 2020 Financial Results Company to Provide Investor Update on November 19 at 4:30pm ET (Details Below) PR Newswire SARASOTA, Fla., Nov. 16, 2020 SARASOTA, Fla. , Nov. 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (Nas...
Infertility technology developer, INVO Bioscience (INVO) has priced its public offering of 3.625M common shares at $3.20/share, for expected gross proceeds of ~$11.6M.Underwriters' over-allotment is an additional 543,750 shares.Nasdaq trading will commence on November 13. Closing date is...
News, Short Squeeze, Breakout and More Instantly...
SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intrava...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 73.2% to $0.0646 on volume of 191,555,690 shares AGBA Group Holding Limited (AGBA) rose 245.0% to $1.38 on volume of 41,065,125 shares TIAN RUIXIANG Holdings Ltd (TIRX) rose 135.2% to $1.14 on volum...
2024-04-18 06:37:00 ET Here’s the Top 3 Reasons to Trade Penny Stocks in 2024 Penny stocks represent a unique investment opportunity for those looking to diversify their portfolios with high-growth potential securities. Characterized by their low price per share, typically under ...